1. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

2. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

3. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

4. Docetaxel/Gemcitabine Administered Every Other Week as First-Line Treatment for Metastatic Breast Cancer: Final Results of a Phase II Trial

5. La fatiga, el insomnio y los trastornos depresivos son frecuentes en la mujer que supera un cáncer

6. Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study.

7. GEICAM convoca la beca Ana Balil dirigida a financiar proyectos de investigación en cáncer de mama

8. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer.

9. Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study

10. Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer. Efficacy and Correlation with Biological Markers in a Phase II, Multicenter Study

«  Inicio   Anterior   1  |  2   Siguiente   Fin  »